

- II. Claims 22-28, 44, 45, and 57, drawn to methods of detecting a TCL-1 abnormality, and a method of diagnosis;
- III. Claims 11, 12, 29, and 30, drawn to antisense nucleic acids to TCL-1, and the composition comprising the antisense nucleic acids;
- IV. Claims 14-16, 31 and 37-42, drawn to antibodies to a TCL-1 protein, the composition of the antibodies, and a method of detecting TCL-1 with antibodies;
- V. Claims 32-36, 43 and 63, drawn to methods of detecting a target sequences;
- VI. Claims 46-49, drawn to methods of treating a disease state;
- VII. Claims 50-54, drawn to methods of treatment using antibodies;
- VIII. Claims 55-56, drawn to oligonucleotide composition; and
- IX. Claims 58-62, drawn to methods of diagnosing a malignancy.

The Examiner contends that the inventions of Group I-IX are distinct, each from the other.

In response, Applicants provisionally elect with traverse the invention of Group I, claims 5-7, 13, 17, 18 and 19.

CONCLUSION

Applicants respectfully request that the foregoing remarks be made of record in the file history of the application. An early allowance of the application is earnestly requested.

Respectfully submitted,

Date: October 19, 2000

S. Leslie Misrock 18,872
S. Leslie Misrock (Reg. No.)

By: Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure